Pfizer Licenses OTC Nexium Rights From AstraZeneca
This article was originally published in The Pink Sheet Daily
Executive Summary
Pfizer will make an upfront payment of $250 million for global rights to market a potential 20 mg OTC version of proton pump inhibitor Nexium, currently available only by prescription. Filing of Rx-to-OTC switch application expected in first half of 2013.